|
CYPER Formulation: Generic Portfolio
This product list is not a limited factor
as we have the capacity & capability to manufacture any
Tablets, Capsules & Topical Preparation.
|
Product
Name
|
Dosage
Form
|
Composition
|
ANTI ANGINAL |
| AMLODIPINE-5 |
TABLETS |
AMLODIPINE (AS AMLODIPINE BESYLATE)5MG |
| PROPANOLOL HCL - 40 |
TABLETS |
PROPANOLOL HCL 40MG |
ANTI DIARRHOEALS |
| FURAZOLIDONE - 100MG |
TABLETS |
FURAZOLIDONE I.P. 100MG |
| LOPERAMIDE HCL – 2MG |
TABLETS |
LOPERAMIDE HCL 2MG |
| OFLOXACIN + ORNIDAZOL |
TABLETS |
OFLOXACIN 200MG + ORNIDAZOL 500MG |
| QUINIDOCHLOR 250MG |
TABLETS |
QUINIDOCHLOR 250MG |
ANTI PROTOZOAL |
| METRONIDAZOLE-200 |
TABLETS |
METRONIDAZOLE 200MG |
| METRONIDAZOLE-400 |
TABLETS |
METRONIDAZOLE 400MG |
| TINIDAZOLE - 500 |
TABLETS |
TINIDAZOLE 500MG |
| ANTI ULCERANTS |
| ALUMINIUM HYDROXIDE GEL 500 MG |
TABLETS |
ALUMINIUM HYDROXIDE GEL 500 MG |
| LANSOPRAZOLE 30MG |
CAPSULES |
LANSOPRAZOLE 30MG |
| OMEPRAZOLE 20MG |
CAPSULES |
OMEPRAZOLE 20MG |
| PANTOPRAZOLE – 20MG |
TABLETS |
PANTOPRAZOLE – 20MG |
| PANTOPRAZOLE – 40MG |
TABLETS |
PANTOPRAZOLE – 40MG |
| RABEPRAZOLE – 10MG |
TABLETS |
RABEPRAZOLE – 10MG |
| RABEPRAZOLE – 20MG |
TABLETS |
RABEPRAZOLE – 20MG |
| RANITIDINE 150MG |
TABLETS |
RANITIDINE 150MG |
| RANITIDINE 150MG |
TABLETS |
RANITIDINE 150MG |
| ANTI T.B |
| ETHAMBUTOL 200 |
TABLETS |
ETHAMBUTOL HYDROCHLORIDE I.P 200MG |
| ETHAMBUTOL 400 |
TABLETS |
ETHAMBUTOL HYDROCHLORIDE I.P 400MG |
| ISONIAZID 100 |
TABLETS |
ISONIAZID 100MG |
| ISONIAZID 300 |
TABLETS |
ISONIAZID 300MG |
| PYRAZINAMIDE 500 |
TABLETS |
PYRAZINAMIDE 500MG |
| PYRAZINAMIDE 750 |
TABLETS |
PYRAZINAMIDE 750MG |
| RIFAMPICIN 150 |
TABLETS |
RIFAMPICIN 150MG |
| RIFAMPICIN 300 |
TABLETS |
RIFAMPICIN 300MG |
| RIFAMPICIN 450 |
TABLETS |
RIFAMPICIN 450MG |
Pages
1 2
3
4
5
6
|
|
|
CYPER
has taken a leading role in developing medicines that
protects and enhances human health throughout India and
in some other parts of world. Our products are result of
CYPER's commitment to research and development...
Read more...
|
|
|